Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on December 17, 2020, covering events occurring on December 9, 2020. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the departure of the interim CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $425,000 annually.
- Annual Performance Bonus: Up to 40% of base salary.
- Equity Grant: Non-qualified stock option for 75,000 shares (exercise price set to closing price on January 4, 2021).
- Equity Vesting: 25% after 12 months, with the remainder vesting monthly over the subsequent 36 months.
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: Satyavrat Shukla, CFA, was appointed Chief Financial Officer, effective January 4, 2021.
- Departure: Stephen DiPalma, who served as Interim CFO, will resign effective January 4, 2021, though he will continue to consult during the transition.
Outlook, Risks, and Contingencies
The filing details specific severance contingencies tied to Mr. Shukla's employment agreement:
- Termination without Cause/Good Reason: Entitles the executive to nine months of base salary, a pro-rated bonus, and up to 12 months of health insurance.
- Change of Control Termination: Entitles the executive to 12 months of base salary, a pro-rated bonus, and accelerated equity vesting (ranging from 25% to 100% of unvested awards depending on tenure prior to the change of control).
- Disability or Death: Entitles the executive to a pro-rated target bonus.
Investor Verification Checklist
- Verify the exact exercise price of the 75,000 stock options once the January 4, 2021, closing price is established.
- Review the full Executive Employment Agreement (to be filed as an exhibit to the 2020 Form 10-K) for detailed definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the transition timeline and any potential overlap in duties between Mr. DiPalma and Mr. Shukla.
- Assess the impact of the new CFO's background (Ziopharm Oncology, Vertex Pharmaceuticals) on the company's capital strategy and investor relations.